Trump turns over new leaf in GOP drug policy with marijuana, psychedelics orders

The Hill reports that the Trump administration has issued executive orders to fast-track psychedelic drug reviews and reschedule medical marijuana, marking a significant shift from traditional Republican drug policy toward reform. The article is bylined to a named journalist at an established national outlet and frames the policy shift as departure from Nixon-era prohibitionism, though the description provided lacks specifics on the actual scope and legal mechanisms of the orders. Independent reporting from AP News, STAT News, CNBC, and The Guardian corroborates the core facts: Trump's reclassification of state-licensed medical marijuana as a less-dangerous drug is being characterized as "the most significant federal advancement in cannabis policy" in decades by industry groups, while The Guardian notes the psychedelics order is "largely symbolic" with limited legal impact despite the high-profile announcement. Readers should monitor FDA implementation timelines, actual clinical trial acceleration for psychedelic treatments, and legislative follow-up needed to fully resolve the conflict between state-licensed cannabis and federal scheduling.